Loading...
•
Jun 30, 2020
Celsion Q2 2020 Earnings Report
Celsion reported a net loss and provided an update on clinical development programs with GEN-1 and ThermoDox.
Key Takeaways
Celsion reported a net loss of $5.3 million for the second quarter of 2020. The company is continuing to follow patients in the Phase III OPTIMA study for overall survival and initiated a Phase II study of GEN-1 in advanced ovarian cancer.
GEN-1 continues to show encouraging results in the OVATION 2 Study.
The Data Safety Monitoring Board recommended the Phase II portion of the OVATION Study proceed with the dose of 100 mg/m2.
Celsion received a recommendation from the independent Data Monitoring Committee to consider stopping the global Phase III OPTIMA Study.
Celsion will continue following patients for overall survival in the Phase III OPTIMA Study.